Bepridil produces prominent bradycardia-dependent QT prolongation in patients with structural heart disease

Journal of Electrocardiology

Volumn 40, Issue 5, 2007, Pages 426-431

  Sadanaga, Tsuneaki ^a   Ogawa, Satoshi ^b  

^a Yatsushiro General Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; SPIRONOLACTONE;

AGED; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART RATE; HOLTER MONITORING; HUMAN; MALE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REGRESSION ANALYSIS; RR INTERVAL;

AGED; BEPRIDIL; BRADYCARDIA; CARDIOMYOPATHIES; FEMALE; HUMANS; LONG QT SYNDROME; MALE; VASODILATOR AGENTS;

EID: 34548161576     PISSN: 00220736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2007.02.007     Document Type: Article

References (21)

1. Levy S., Cointe R., Metge M., et al. Bepridil for recurrent sustained ventricular tachycardias: assessment using electrophysiologic testing. Am J Cardiol 546 (1984) 579
2. Brembilla-Perrot B., Aliot E., Clementy J., et al. Evaluation of bepridil efficacy by electrophysiologic testing in patients with recurrent ventricular tachycardia: comparison of two regimens. Cardiovasc Drugs Ther 6 (1992) 187
3. Prystowsky E.N. Effects of bepridil on cardiac electrophysiologic properties. Am J Cardiol 69 (1992) 63D
4. Perelman M.S., McKenna W.J., Rowland E., et al. A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. Br Heart J 58 (1987) 339
5. Fujiki A., Tsuneda T., Sugao M., et al. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 924 (2003) 472
6. Nakazato Y., Yasuda M., Sasaki A., et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 69 (2005) 44
7. Yoshida T., Niwano S., Inuo K., et al. Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. Pacing Clin Electrophysiol 26 (2003) 314
8. Manouvrier J., Sagot M., Caron C., et al. Nine cases of torsade de pointes with bepridil administration. Am Heart J 111 (1986) 1005
9. Coumel P. Safety of bepridil: from review of the European data. Am J Cardiol 69 (1992) 75D
10. Yasuda M., Nakazato Y., Sasaki A., et al. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 70 (2006) 662
11. Kodama I., Suzuki R., Kamiya K., et al. Effects of long-term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle. Br J Pharmacol 107 (1992) 502
12. Sager P.T., Uppal P., Follmer C., et al. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 88 (1993) 1063
13. Gill A., Flaim S.F., Damiano B.P., et al. Pharmacology of bepridil. Am J Cardiol 69 (1992) 11
14. Anno T., Furuta T., Itho M., et al. Effects of bepridil on the electrophysiological properties of guinea-pig ventricular muscles. Br J Pharmacol 81 (1984) 589
15. Berger F., Borchard U., and Hafner D. Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol 339 (1989) 638
16. Wang J.C., Kiyosue T., Kiriyama K., et al. Bepridil differentially inhibits two delayed rectifier K (+) currents, I (Kr) and I (Ks), in guinea-pig ventricular myocytes. Br J Pharmacol 128 (1999) 1733
17. Kobayashi S., Reien Y., Ogura T., et al. Inhibitory effect of bepridil on hKv1.5 channel current: comparison with amiodarone and E-4031. Eur J Pharmacol 430 (2001) 149
18. Sadanaga T., Ogawa S., Okada Y., et al. Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy. Am Heart J 126 (1993) 114
19. Okada Y., Ogawa S., Sadanaga T., et al. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. J Am Coll Cardiol 27 (1996) 84
20. Sadanaga T., Sadanaga F., Yao H., et al. Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: significance of bradycardia-dependent QT prolongation. J Electrocardiol 37 (2004) 267
21. Lepeschkin E., and Surawicz B. The measurement o the Q-T interval of the electrocardiogram. Circulation 6 (1952) 378